Shot in arm for Noxopharm
Positive results for a product promising a breakthrough in the use of mRNA drugs sent Noxopharm shares skyrocketing by 50 per cent on Wednesday morning. New data showed that SOF-VAC – Noxopharm’s proprietary asset – significantly reduced mRNA-driven inflammation in animals. In the animal study, inflammation from mRNA was reduced by around 50 per cent … Read more